Physician profile
James E Binkard
NPI 1255343851
$2,051.44
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $772 · 2021: $17.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $493.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $298.36 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $294.78 | 2019-2020 | |
| Novo Nordisk INC | $182.06 | 2019-2020 | |
| Allergan, INC. | $115.25 | 2019-2020 | |
| Lilly USA, LLC | $112.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.70 | 2019 | |
| Viiv Healthcare Company | $80.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $72.75 | 2019 | |
| Pfizer INC. | $68.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $38.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.47 | 2019 | |
| Shire North American Group INC | $21.47 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2020 | |
| Medtronic, INC. | $17.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Binkard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.